Tranzyme Pharma announced confident top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic clients with gastroparesis, a serious mess characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically pointed and statistically eloquent as of an individual or a society.
amelioration in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.

More: - Continued here